A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Ravulizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 17 Apr 2023 This trial has been Completed in Austria, According to European Clinical Trials Database record.
- 14 Apr 2023 Status changed from active, no longer recruiting to completed.
- 04 Mar 2023 This trial has been Completed in Belgium, According to European Clinical Trials Database record.